• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

由于酵母聚糖结合的扩增转化酶对内源调节机制具有抗性,导致替代补体途径激活。

Activation of the alternative complement pathway due to resistance of zymosan-bound amplification convertase to endogenous regulatory mechanisms.

作者信息

Fearon D T, Austen K F

出版信息

Proc Natl Acad Sci U S A. 1977 Apr;74(4):1683-7. doi: 10.1073/pnas.74.4.1683.

DOI:10.1073/pnas.74.4.1683
PMID:266208
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC430857/
Abstract

The surface of zymosan (Zy), by affording a protected microenvironment for C3b and the amplification convertase stabilized by properdin, P,C3b,Bb, shifts the alternative complement pathway from slow fluid phase turnover to the amplification phase of its expression. This mode of activation is in contradistinction to that of the classical pathway, which follows conversion of a proenzyme, Cl, to its active form, C1. Under conditions in which the control proteins, C3b inactivator (C3bINA) and beta1H, completely, inactivated C3b on the sheep erythrocyte intermediate, EAC4b,3b, the activity of C3b bound to Zy,ZyC3b, was diminished by only one-third. Further, when ZyC3b was converted to ZyC3b,Bb,P there was an additional point of deregulation in that the convertase was resistant to beta1H-mediated decay-dissociation while P,C3b,Bb on the sheep erythrocyte exhibited the usual susceptibility to beta1H. That Zy alone could indeed promote rapid C3 cleavage by the alternative pathway through assembly and protection of the amplification convertase on its surface was demonstrated with a mixture of alternative pathway proteins, C3,B,D,P, C3bINA, and beta1H, that had each been purified to homogeneity. Interaction of these proteins at one-tenth their relative serum concentrations with Zy permitted low-grade inactivation of C3 and B to advance to the level of amplification after a 15 min lag period. Because the reaction of the purified proteins proceeded spontaneously when either regulatory protein was deleted, the effect of Zy was attributed to deregulation rather than to conversion of one of the proteins to a specific initiating state. The alternative pathway, through the normal presence of D, interacts with a microbial surface, such as Zy, to amplify deposition of C3b by circumvention of endogenous regulatory mechanisms, thereby augmenting host defense.

摘要

酵母聚糖(Zy)的表面通过为C3b以及由备解素稳定的扩增转化酶P、C3b、Bb提供一个受保护的微环境,将替代补体途径从缓慢的液相周转转变为其表达的扩增阶段。这种激活模式与经典途径相反,经典途径是前体酶C1转化为其活性形式C1。在控制蛋白C3b灭活剂(C3bINA)和β1H完全灭活绵羊红细胞中间体EAC4b、3b上的C3b的条件下,与Zy结合的C3b(ZyC3b)的活性仅降低了三分之一。此外,当ZyC3b转化为ZyC3b、Bb、P时,出现了另一个失调点,即转化酶对β1H介导的衰变解离具有抗性,而绵羊红细胞上的P、C3b、Bb对β1H表现出通常的敏感性。用已各自纯化至同质的替代途径蛋白C3、B、D、P、C3bINA和β1H的混合物证明,单独的Zy确实可以通过在其表面组装和保护扩增转化酶来促进替代途径对C3的快速裂解。这些蛋白以其相对血清浓度的十分之一与Zy相互作用,经过15分钟的延迟期后,允许C3和B的低水平失活进展到扩增水平。因为当删除任何一种调节蛋白时,纯化蛋白的反应都会自发进行,所以Zy的作用归因于失调,而不是将其中一种蛋白转化为特定的起始状态。替代途径通过D的正常存在,与微生物表面(如Zy)相互作用,通过规避内源性调节机制来放大C3b的沉积,从而增强宿主防御。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b597/430857/953b10903d29/pnas00026-0389-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b597/430857/953b10903d29/pnas00026-0389-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b597/430857/953b10903d29/pnas00026-0389-a.jpg

相似文献

1
Activation of the alternative complement pathway due to resistance of zymosan-bound amplification convertase to endogenous regulatory mechanisms.由于酵母聚糖结合的扩增转化酶对内源调节机制具有抗性,导致替代补体途径激活。
Proc Natl Acad Sci U S A. 1977 Apr;74(4):1683-7. doi: 10.1073/pnas.74.4.1683.
2
Activation of the alternative complement pathway with rabbit erythrocytes by circumvention of the regulatory action of endogenous control proteins.通过规避内源性控制蛋白的调节作用,利用兔红细胞激活替代补体途径。
J Exp Med. 1977 Jul 1;146(1):22-33. doi: 10.1084/jem.146.1.22.
3
Pathways of complement activation in membranoproliferative glomerulonephritis and allograft rejection.膜增生性肾小球肾炎和同种异体移植排斥反应中补体激活途径。
Transplant Proc. 1977 Mar;9(1):729-39.
4
A molecular basis of activation of the alternative pathway of human complement.人类补体替代途径激活的分子基础。
Adv Exp Med Biol. 1979;120B:3-17.
5
Control of the amplification convertase of complement by the plasma protein beta1H.血浆蛋白β1H对补体扩增转化酶的调控
Proc Natl Acad Sci U S A. 1976 Sep;73(9):3268-72. doi: 10.1073/pnas.73.9.3268.
6
Complement C3 convertase: cell surface restriction of beta1H control and generation of restriction on neuraminidase-treated cells.补体C3转化酶:β1H调控的细胞表面限制及神经氨酸酶处理细胞上限制的产生
Proc Natl Acad Sci U S A. 1978 May;75(5):2416-20. doi: 10.1073/pnas.75.5.2416.
7
Alternative pathway of complement: recruitment of precursor properdin by the labile C3/C5 convertase and the potentiation of the pathway.补体替代途径:不稳定的C3/C5转化酶招募前体备解素并增强该途径。
J Exp Med. 1976 Oct 1;144(4):1076-93. doi: 10.1084/jem.144.4.1076.
8
Surface-associated heparin inhibits zymosan-induced activation of the human alternative complement pathway by augmenting the regulatory action of the control proteins on particle-bound C3b.表面相关肝素通过增强控制蛋白对颗粒结合C3b的调节作用,抑制酵母聚糖诱导的人替代补体途径的激活。
J Exp Med. 1979 Nov 1;150(5):1202-15. doi: 10.1084/jem.150.5.1202.
9
Regulation by membrane sialic acid of beta1H-dependent decay-dissociation of amplification C3 convertase of the alternative complement pathway.膜唾液酸对替代补体途径中C3转化酶β1H依赖性衰变解离的调节作用。
Proc Natl Acad Sci U S A. 1978 Apr;75(4):1971-5. doi: 10.1073/pnas.75.4.1971.
10
Regulation of the amplification C3 convertase of human complement by an inhibitory protein isolated from human erythrocyte membrane.从人红细胞膜分离出的一种抑制性蛋白对人补体C3转化酶扩增的调节作用。
Proc Natl Acad Sci U S A. 1979 Nov;76(11):5867-71. doi: 10.1073/pnas.76.11.5867.

引用本文的文献

1
Interactions Between the Innate and Adaptive Immune Responses.先天性免疫反应与适应性免疫反应之间的相互作用
Adv Exp Med Biol. 2025;1476:297-308. doi: 10.1007/978-3-031-85340-1_12.
2
Bradykinin B1 receptor signaling triggers complement activation on endothelial cells.缓激肽B1受体信号传导触发内皮细胞上的补体激活。
Front Immunol. 2025 Feb 7;16:1527065. doi: 10.3389/fimmu.2025.1527065. eCollection 2025.
3
Modeling complement activation on human glomerular microvascular endothelial cells.在人肾小球微血管内皮细胞上建模补体激活。

本文引用的文献

1
Chromatographic resolution of the first component of human complement into three activities.将人类补体的第一成分通过色谱法分离为三种活性。
J Exp Med. 1963 Jun 1;117(6):983-1008. doi: 10.1084/jem.117.6.983.
2
The properdin system and immunity. I. Demonstration and isolation of a new serum protein, properdin, and its role in immune phenomena.备解素系统与免疫。I. 一种新的血清蛋白——备解素的证实、分离及其在免疫现象中的作用。
Science. 1954 Aug 20;120(3112):279-85. doi: 10.1126/science.120.3112.279.
3
Formation and functional significance of a molecular complex derived from the second and the fourth component of human complement.
Front Immunol. 2023 Oct 25;14:1206409. doi: 10.3389/fimmu.2023.1206409. eCollection 2023.
4
Distinction of early complement classical and lectin pathway activation quantification of C1s/C1-INH and MASP-1/C1-INH complexes using novel ELISAs.采用新型 ELISA 技术对早期补体经典途径和凝集素途径激活进行区分——定量检测 C1s/C1-INH 和 MASP-1/C1-INH 复合物。
Front Immunol. 2022 Nov 4;13:1039765. doi: 10.3389/fimmu.2022.1039765. eCollection 2022.
5
Physiology and pathology of the C3 amplification cycle: A retrospective.C3 扩增循环的生理学和病理学:回顾。
Immunol Rev. 2023 Jan;313(1):217-224. doi: 10.1111/imr.13165. Epub 2022 Nov 21.
6
Development of a Sensitive Assay to Screen Nanoparticles for Complement Activation.一种用于筛选纳米颗粒补体激活的灵敏检测方法的开发。
ACS Biomater Sci Eng. 2020 Sep 14;6(9):4903-4915. doi: 10.1021/acsbiomaterials.0c00722. Epub 2020 Jul 6.
7
Advances of the experimental models of idiopathic membranous nephropathy (Review).特发性膜性肾病的实验模型研究进展(综述)。
Mol Med Rep. 2020 May;21(5):1993-2005. doi: 10.3892/mmr.2020.11014. Epub 2020 Mar 9.
8
Upregulation and release of soluble fms-like tyrosine kinase receptor 1 mediated by complement activation in human syncytiotrophoblast cells.补体激活介导人合体滋养层细胞可溶性 fms 样酪氨酸激酶受体 1 的上调和释放。
Am J Reprod Immunol. 2018 Nov;80(5):e13033. doi: 10.1111/aji.13033. Epub 2018 Aug 12.
9
The properdin pathway: an "alternative activation pathway" or a "critical amplification loop" for C3 and C5 activation?备解素途径:C3 和 C5 激活的“替代激活途径”还是“关键扩增环”?
Semin Immunopathol. 2018 Jan;40(1):15-35. doi: 10.1007/s00281-017-0661-x. Epub 2017 Nov 22.
10
Blockage of the lysosome-dependent autophagic pathway contributes to complement membrane attack complex-induced podocyte injury in idiopathic membranous nephropathy.溶酶体依赖性自噬途径的阻断导致补体膜攻击复合物诱导的特发性膜性肾病足细胞损伤。
Sci Rep. 2017 Aug 17;7(1):8643. doi: 10.1038/s41598-017-07889-z.
源自人补体第二和第四成分的分子复合物的形成及其功能意义。
J Exp Med. 1967 Feb 1;125(2):359-80. doi: 10.1084/jem.125.2.359.
4
Methods for the separation, purification and measurement of nine components of hemolytic complement in guinea-pig serum.豚鼠血清中溶血补体九种成分的分离、纯化及测定方法
Immunochemistry. 1966 Mar;3(2):111-35. doi: 10.1016/0019-2791(66)90292-8.
5
C3 inactivator of man. I. Hemolytic measurement by the inactivation of cell-bound C3.人C3灭活剂。I. 通过细胞结合C3的灭活进行溶血测定。
J Immunol. 1969 Mar;102(3):533-43.
6
The reliability of molecular weight determinations by dodecyl sulfate-polyacrylamide gel electrophoresis.通过十二烷基硫酸钠-聚丙烯酰胺凝胶电泳测定分子量的可靠性。
J Biol Chem. 1969 Aug 25;244(16):4406-12.
7
Complement dependent immune phagocytosis. I. Requirements for C'1, C'4, C'2, C'3.补体依赖性免疫吞噬作用。I. 对C'1、C'4、C'2、C'3的需求
Exp Cell Res. 1968 Jul;51(1):45-67. doi: 10.1016/0014-4827(68)90158-4.
8
C3b inactivator of man. II. Fragments produced by C3b inactivator cleavage of cell-bound or fluid phase C3b.人C3b灭活因子。II. 细胞结合型或液相C3b经C3b灭活因子裂解产生的片段
J Immunol. 1971 Sep;107(3):742-50.
9
Properdin factor D: characterization of its active site and isolation of the precursor form.备解素因子D:其活性位点的表征及前体形式的分离。
J Exp Med. 1974 Feb 1;139(2):355-66. doi: 10.1084/jem.139.2.355.
10
The relationship of glycine-rich -glycoprotein to factor B in the properdin system and to the cobra factor-binding protein of huan serum.富含甘氨酸的糖蛋白与备解素系统中的B因子以及人血清眼镜蛇因子结合蛋白的关系。
J Exp Med. 1973 Feb 1;137(2):424-37. doi: 10.1084/jem.137.2.424.